CSIMarket
 
Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 

Cytokinetics Incorporated

Officers & Directors




Executive Team:
- Robert I. Blum, President and Chief Executive Officer
- Fady Ibraham Malik, Executive Vice President, Research & Development and Chief Medical Officer
- Ching Jaw, Senior Vice President, Chief Financial Officer & Chief Business Officer
- Diane Weiser, Senior Vice President, Human Resources & Corporate Communications
- Bradley Morgan, Senior Vice President, General Counsel, and Corporate Secretary
- Bruce Wentworth, Senior Vice President, Commercial Operations
- Heather Adams, Chief Accounting Officer

Board of Directors:
- Robert I. Blum, President and Chief Executive Officer of Cytokinetics
- Michael W. Bonney, former CEO and Chairman of Cubist Pharmaceuticals
- Lila M. Chakraborty, Ph.D., Executive Partner at Arix Bioscience and former Senior Vice President at Bristol-Myers Squibb
- Sandford Drexel "Sandy" Smith, Managing Director at Capital Research and Management Company
- J. Donald deBethizy, Ph.D., former CEO of Targacept and Venture Partner at Hatteras Venture Partners
- Wendy L. Dixon, Ph.D., former Executive Vice President and Chief Marketing Officer at Bristol-Myers Squibb
- Dr. Sarah Schlesinger, Associate Dean of Biological Sciences at Columbia University
- Kurt von Emster, Managing Partner of Abingworth Management Limited.

Cytokinetics Incorporated currently has 202 employees.

  News about Cytokinetics Incorporated Key Personnel

Cytokinetics Unites with Global Organizations to Advocate for Rare Diseases Amidst Challenging Financial Climate



Cytokinetics, Incorporated, a biopharmaceutical company, recently announced its partnership with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) in support of Rare Disease Day. This international campaign aims to increase awareness and public understanding of rare diseases, highlighting the challenges faced by over 300 million people living with such conditions worldwide. Additionally, Cytokinetics' financial performance has been notably affected, as the company recorded a cumulative net loss of $527 million during the 12-month period ending in the third quarter of 2023, contributing to a negative return on investment (ROI) of -67.49%.<...






CYTK Management Effectiveness CYTK Revenue per Employee CYTK Income per Employee


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com